MedTrace Logo

Comparative Study of Thrombocytopenia in Plasmodium Vivax and Falciparum Malaria

NCT07122232 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 177

Last updated 2025-08-14

No results posted yet for this study

Summary

This study aimed to compare platelet count patterns in patients infected with either Plasmodium vivax or Plasmodium falciparum, the two most common malaria species in Pakistan. Thrombocytopenia (low platelet count) is a common complication of malaria and can help in identifying disease severity. We conducted this research at a tertiary care hospital in Peshawar, Pakistan, from April to September 2023. A total of 171 adult patients with confirmed malaria infections were enrolled. We measured their platelet counts at admission, day 3, and day 7, and analyzed the severity and progression of thrombocytopenia. The study found that while P. vivax was more common, P. falciparum was more likely to cause severe thrombocytopenia. Understanding these differences helps healthcare providers identify high-risk patients earlier and manage malaria more effectively. The study was approved by the institutional review board of Lady Reading Hospital, Peshawar.

Conditions

Sponsors & Collaborators

  • Lady Reading Hospital, Pakistan

    collaborator OTHER_GOV

  • Rafiullah Hotak

    lead OTHER

Principal Investigators

  • Rafiullah Hotak, MBBS · Nangarhar University faculty of medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2023-09-30
Completion
2023-09-30

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07122232 on ClinicalTrials.gov